CaMKII signaling in physiology, heart failure and arrhythmias
CaMKII signaling in physiology, heart failure and arrhythmias
批准号:
10335191
负责人:
MARK E ANDERSON
金额:
$96.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-22 至 2022-09-30
关键词:
Animal ModelArrhythmiaAsthmaAwardBiologyBrain-Derived Neurotrophic FactorCRISPR/Cas technologyCa(2+)-Calmodulin Dependent Protein KinaseCalciumCardiovascular DiseasesCellsComplexComputer ModelsDataDilated CardiomyopathyDiseaseDrosophila genusDrosophila melanogasterGoalsHealthHeartHeart failureInjuryKnowledgeLongevityMetabolicMetabolismMitochondriaModelingMolecularMusNatureOrganellesOutcomeOxidantsOxidative StressParaquatPathologicPathway interactionsPhenotypePhysiologicalPhysiologyProductionProtein IsoformsPublic HealthReactive Oxygen SpeciesResearchResearch PersonnelResistanceRoleSepsisSignal TransductionSkeletal MuscleTestingThinnessWeight Gainantioxidant therapyexercise capacityfightingflyimaging studyimprovedinnovationinsightinsulin sensitivitymetabolic abnormality assessmentmortalitymyocardial injuryoxidant stressoxidationphosphoproteomicspreventprogramsresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Heart failure and arrhythmias occur together, are marked by increased reactive oxygen species (ROS), and
are major, unsolved public health problems. Despite this, ROS can be beneficial. However, clear molecular
mechanisms supporting the benefits of ROS are lacking. The potential for ROS to be ‘good and bad’ is called
the ROS paradox. This Outstanding Investigator Award application will propose innovative approaches to
understanding and dissecting healthy from pathological ROS. The goal of this research program is to test a
disruptive concept that ROS activation of the multifunctional calcium and calmodulin kinase II (CaMKII) by
isoform and organelle selective pathways determine physiological and pathological outcomes of ROS
signaling. We discovered that oxidation activates CaMKII (ox-CaMKII, Erickson Cell 2008) and established
that ox-CaMKII, the major CaMKII isoform in heart, causes heart failure and arrhythmias. Our newest studies
extended these findings to show that ox-CaMKII also contributes to asthma. In sharp contrast, our new
preliminary data indicate that ox-CaMKII, an isoform enriched in skeletal muscle, is beneficial and enhances
endurance, insulin sensitivity, lean phenotype, PGC-1, and expression or brain derived neurotrophic factor
(BDNF), a myokine that improves exercise capacity and protects against myocardial injury. Our group
discovered that CaMKII is present in mitochondria and that mitochondrial-targeted inhibition of CaMKII protects
against common forms of myocardial injury associated with high ROS (Joiner Nature 2012). Here we propose
to pursue new models of global (i.e. body-wide) mitochondrial CaMKII inhibition in flies (Drosophila
melanogaster) and mice developed for the proposed OIA studies. Mitochondrial CaMKII inhibited flies have a
prolonged lifespan and resistance to paraquat induced oxidant injury, while mice with global CaMKII inhibition
have reduced mortality in sepsis and increased weight gain. We performed new phosphoproteomic and
metabolic analyses that identified unanticipated mitochondrial CaMKII targets with central roles in metabolism
and ROS production. Our preliminary computational modeling and experimental data suggest that
physiological activation of mitochondrial CaMKII contributes to a beneficial metabolic fight or flight response
that increases ATP; however, sustained and excessive mitochondrial CaMKII activity causes dilated
cardiomyopathy due to loss of complex 1 and ATP deficiency. We and our collaborators will use state of the
art computer modeling, imaging and metabolic studies, and generate a panel of mouse and Drosophila models
using CRISPR/Cas9 to dissect contributions of CaMKII to specific targets relevant to heart failure, arrhythmias
and to health. This research program requires an R35, or similar, mechanism because of its highly innovative
concept that challenges current paradigms in CaMKII and ROS biology, the need to manage large amounts of
data and generate new animals models, and the requirement for a prolonged timeframe.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Myocardial death and dysfunction after ischemia-reperfusion injury require CaMKIIδ oxidation.
缺血再灌注损伤后的心肌死亡和功能障碍需要 CaMKIIδ 氧化。
DOI:
10.1038/s41598-019-45743-6
发表时间:
2019
期刊:
Scientific reports
影响因子:
4.6
作者:
[Wu,Yuejin, Wang,Qinchuan, Feng,Ning, Granger,JonathanM, Anderson,MarkE]
通讯作者:
Anderson,MarkE
HCN channels sense temperature and determine heart rate responses to heat.
HCN 通道感知温度并确定心率对热的反应。
DOI:
10.1101/2023.09.02.556046
发表时间:
2023
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Wu,Yuejin, Wang,Qinchuan, Granger,Jonathan, Gaido,OscarReyes, Aguilar,EricNunez, Ludwig,Andreas, Moroni,Anna, Bianchet,MarioA, Anderson,MarkE]
通讯作者:
Anderson,MarkE
DOI:
10.1038/s41592-023-01840-z
发表时间:
2023-05
期刊:
NATURE METHODS
影响因子:
48
作者:
[Zou, Roger S., Liu, Yang, Gaido, Oscar E. Reyes, Konig, Maximilian F., Mog, Brian J., Shen, Leo L., Aviles-Vazquez, Franklin, Marin-Gonzalez, Alberto, Ha, Taekjip]
通讯作者:
Ha, Taekjip
DOI:
10.1126/science.aan3303
发表时间:
2018-12-21
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
[Guo A, Wang Y, Chen B, Wang Y, Yuan J, Zhang L, Hall D, Wu J, Shi Y, Zhu Q, Chen C, Thiel WH, Zhan X, Weiss RM, Zhan F, Musselman CA, Pufall M, Zhu W, Au KF, Hong J, Anderson ME, Grueter CE, Song LS]
通讯作者:
Song LS
DOI:
10.1016/j.jbc.2022.102579
发表时间:
2022-11
期刊:
JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子:
4.8
作者:
[Rocco-Machado, Nathalia, Lai, Lo, Kim, Geumsoo, He, Yi, Luczak, Elizabeth D., Anderson, Mark E., Levine, Rodney L.]
通讯作者:
Levine, Rodney L.
共 7 条
CaMKII signaling in physiology, heart failure and arrhythmias
-
批准号:10077577
-
项目类别:
-
资助金额:$119.86万
-
财政年份:2018
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII signaling in physiology, heart failure and arrhythmias
-
批准号:10026490
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2018
-
负责人:MARK E ANDERSON
-
依托单位:
2014 Cardiac Regulatory Mechanisms Gordon Research Conference & Gordon Research S
-
批准号:8784793
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
Mitochondrial Calmodulin Kinase II in Physiology and Disease
-
批准号:8909894
-
项目类别:
-
资助金额:$39.69万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:9115686
-
项目类别:
-
资助金额:$38.79万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8909874
-
项目类别:
-
资助金额:$39.53万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8915241
-
项目类别:
-
资助金额:$38.21万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
Mitochondrial Calmodulin Kinase II in Physiology and Disease
-
批准号:8915239
-
项目类别:
-
资助金额:$39.22万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
2012 Cardiac Regulatory Mechanisms Gordon Research Conference and Gordon Research
-
批准号:8316613
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8628170
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8812901
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8271667
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8449636
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:7695210
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8575675
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8056075
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8269846
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
TESTING AND CALIBRATION OF SPECTROMETER FUNCTIONS
-
批准号:7954631
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
RUNNING POSSIBLE COLLABORATORY EXPERIMENTS
-
批准号:7954627
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:7891241
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
海外基金